Overall, we described nine pathogenic variants from databases of clinical interest in LRRK2, PRKN and PINK1 in a total of 26 samples (13 PD, 1 PSP and 12 controls, all heterozygous) representing 1.7% of the total cohort (Table 3). This evidence concerns the gene LRRK2 and supranuclear palsy, progressive, 1.